https://sciex.com/content/SCIEX/na/us/en

AB Sciex is doing business as SCIEX. © 2010-2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license. Beckman Coulter® is being used under license. Product(s) may not be available in all countries. For information on availability, please contact your local representative. For research use only. Not for use in diagnostic procedures.

<a href="https://community.sciex.com/author/commmunitysuperuser/" target="_self">SCIEX Community</a>

SCIEX Community

Facebook
X (Twitter)
LinkedIn
Share


Comprehensive Therapeutic Protein Characterization Using One Single Method

Jun 19, 2017 | Biopharma, Blogs | 0 comments

Get to know how CESI-MS will allow you to quickly and accurately characterize protein therapeutics for attributes in a single method by downloading this discovery kit.

The Biologics Characterization and Discovery Kit Includes:

  • Executive Summary
  • Tech Note: A Unified Workflow for Monoclonal Antibody Charge Heterogeneity Purity, and Molecular Weight Analyses
  • Webinar: Biologics Characterization and Discovery by CESI-MS
  • Tech Note: CESI-MS Comparison of Tryptic Digests from Different Monoclonal Antibodies in an Assessment of Biosimilarity
  • Tech Note: Structural Characterization of ADCs by a Combination of Intact, Middle-up, and Bottom-up Approaches using CESI-MS

A Unified Workflow for Monoclonal Antibody Charge Heterogeneity Purity, and Molecular Weight Analyses
Discover how combining the unique separation capabilities of capillary zone electrophoresis (CZE) with the advantages of an MS-based detector provide high-resolution structural information and accurate molecular weight information. Using CESI-MS and stand-alone CE functionality of the CESI 8000 Plus system, researchers demonstrate powerful methods to characterize intact and reduced IgG forms.

CESI-MS Comparison of Tryptic Digests from Different Monoclonal Antibodies in an Assessment of Biosimilarity
Includes a summary of work recently published by the research group LSMIS at the University of Strasbourg. It focuses on how CESI-MS can be used to characterize and compare a marketed reference mAb with other biosimilar candidates. A CESI-MS protocol for biosimilarity studies of mAbs has been developed which highlights 100% amino acid sequence coverage & PTM “hot spot” mapping and ID.

Structural Characterization of Antibody-Drug Conjugates (ADCs) by a Combination of Intact, Middle-up and Bottom-up Approaches using CESI-MS
This tech note also summarizes work recently published by the research group at LSMIS. In this tech note, discover how CESI-MS can be used to characterize a gold standard cysteine-linked ADC, brentuximab vedotin. Want to learn more about highlighting DAR calculation under native conditions; drug distribution, drug location, 100% coverage and PTMs? It’s all here.

Visit our website to learn more about CE instruments >

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

Community Manager
Tags
Biopharmabiotherapeutic developmentblazechargecompanycoupledevelopmentjobmachinemassmoneynewnumberpowerproteinrapidsystemtechnologytimevariantwork

0 Comments

Submit a Comment

SCIEX Now™ Support Network

The Destination for All Your Support Needs

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

Echo and Echo MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.
Empower is a trademark of Waters Corporation used under license. © DH Tech. Dev. Pte. Ltd.

Wordpress Social Share Plugin powered by Ultimatelysocial